SOUNDTRACK-E: A PHASE 1/2 OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AZD0486 MONOTHERAPY OR COMBINATION THERAPY IN PATIENTS WITH MATURE B-CELL MALIGNANCIES

EHA Library, Joanna Rhodes, 4161721

REAL-WORLD ZANUBRUTINIB TREATMENT PATTERNS IN CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA AMONG US COMMUNITY ONCOLOGY PATIENTS WITH PRIOR ACALABRUTINIB THERAPY

EHA Library, Jing-Zhou Hou, 4161722

HIGH LYMPHOCYTE COUNT MAY BE ASSOCIATED WITH BLEEDING RISK IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH BRUTON'S TYROSINE KINASE INHIBITORS

EHA Library, Ivan Krecak, 4161724

VIRTUAL PATIENT SIMULATION IMPROVES CLINICAL DECISION-MAKING IN THE MANAGEMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Victoria Harvey-Jones, 4161726

THE DEMOGRAPHICS OF PATIENT POPULATION WITH CLL ENROLLED ON CLINICAL TRIALS - THE STANFORD 10-YEAR EXPERIENCE

EHA Library, Anna Oh, 4161727

ADVERSE EVENTS OF INTEREST WITH ZANUBRUTINIB VS FIXED-DURATION COMBINATION OF VENETOCLAX + OBINUTUZUMAB IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Nicole Lamanna, 4161728

BREAST CANCER IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: IMPACT ON DISEASE COURSE AND SURVIVAL OUTCOMES - A RETROSPECTIVE STUDY

EHA Library, Shai Levi, 4161729

CLINICAL OUTCOMES OF CLL PATIENTS TREATED WITH VENETOCLAX AFTER TREATMENT WITH IBRUTINIB - DATA FROM THE OBSERVATIONAL STUDY VERVE

EHA Library, Ingo Schwaner, 4161730

A NETWORK META-ANALYSIS (NMA) OF EFFICACY OF ZANUBRUTINIB VERSUS FIXED-DURATION ACALABRUTINIB PLUS VENETOCLAX IN TREATMENT-NAÏVE (TN) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Mazyar Shadman, 4161731

USE OF ACALABRUTINIB AS FIRST LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKAEMIA IN ROUTINE CLINICAL PRACTICE IN SPAIN: THE PICAROS STUDY.

EHA Library, Lucrecia Yañez, 4161733

Preparing for the Future of Time-Limited Therapy in Chronic Lymphocytic Leukaemia: The Impact of Education on Clinical Skills and Decision-Making With Modern Regimens

EHA Library, Carmine DeLuca, 4161735

THE EFFECTS OF AN ONLINE CURRICULUM BASED APPROACH TO CME ON HEMATOLOGIST/ONCOLOGISTS' ABILITY TO TREAT PATIENTS WITH BTK INHIBITORS FOR B-CELL MALIGNANCIES

EHA Library, Victoria Harvey-Jones, 4161736

REAL-WORLD BRUTON TYROSINE KINASE INHIBITOR USE AND CLINICAL OUTCOMES AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

EHA Library, Jing-Zhou Hou, 4161737

THE CLINICAL AND HEMATOPATHOLOGY ANALYSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH T(18;22)(Q21;Q11)/IGL::BCL2

EHA Library, Shaobin Yang, 4161738

THE ASSOCIATION BETWEEN LPL DELETION, TP53 MUTANT, ZAP 70 EXPRESSION AND RESPONSE TO IBRUTINIB IN NEWLY DIAGNOSED HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Maher Salamoon, 4161739

VENETOCLAX-RITUXIMAB FIXED DURATION COMBINATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) ICLUDING THOSE AFTER BTK INHIBITORS IN A REAL-WORLD SETTING

EHA Library, Maria Dimou, 4161740

PILOT STUDY OF TARGETED NANOPORE SEQUENCING FOR TP53 MUTATION DETECTION IN CLL: A SINGLE-CENTRE EXPERIENCE FROM CENTRAL KAZAKHSTAN

EHA Library, Aidos Akhmetali, 4161741

ANTI-DPPX ENCEPHALITIS IN CLL - A NEW ZEALAND PERSPECTIVE

EHA Library, Te Apatuoterangi McCrea, 4161742

A QUALITATIVE STUDY TO EXPLORE THE PATIENT EXPERIENCE OF CONTINUOUS COVALENT BRUTON TYROSINE KINASE (BTK) INHIBITORS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): STUDY METHODOLOGY

EHA Library, Talha Munir, 4161743

SINGLE-CENTRE EXPERIENCE USING A RAPID VENETOCLAX DOSE ESCALATION STRATEGY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA

EHA Library, David Parfrey, 4161744

THE AGE AND TYPE OF THERAPY NEGATIVELY INFLUENCE THE FORMATION OF ANTIBODIES TO SARS-COV-2 VIRUS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS (CLPD)

EHA Library, Tatyana Glazanova, 4161745

IGVH MUTATIONAL STATUS AS A PROGNOSTIC FACTOR AFFECTING RELAPSE-FREE SURVIVAL AND TREATMENT-FREE INTERVAL IN CLL PATIENTS: SINGLE-CENTER EXPERIENCE WITH 110 CASES

EHA Library, Taner Tan, 4161746

EVALUATION OF ADVANCED PRATICE NURSE'S MANAGEMENT OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA. PRELIMINARY RESULTS

EHA Library, Christine Tosello, 4161747

FRONTLINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A SINGLE CENTER EXPERIENCE FOCUSING ON VENETOCLAX INITIATION TIMING AND TOXICITY PROFILE

EHA Library, Andrea Nunzi, 4161748

VENETOCLAX ADMINISTRATION IN CLL PATIENTS WITH ESTABLISHED HEART FAILURE: A CASE SERIES WITH CLOSE COLLABORATION BETWEEN CARDIO-ONCOLOGY

EHA Library, Li Yuan Chan, 4161749

NEXT-GENERATION BTK INHIBITORS IN CLL-ASSOCIATED MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: TWO CASE REPORTS

EHA Library, Yuting Huang, 4161750

INVOLVEMENT OF THE CENTRAL NERVOUS SYSTEM IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Tatyana Byalik, 4161751

OBINUTUZUMAB PLUS CHLORAMBUCIL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA - REAL LIFE EXPERIENCE

EHA Library, Tamara Bibić, 4161752

DYNAMIC EVALUATION OF VENETOCLAX-RELATED TOXICITIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN THE REAL-LIFE SETTING AT A SINGLE-CENTER IN BELARUS

EHA Library, Tatsiana Talako, 4161753

ANALYSIS OF UNFAVORABLE EVOLUTION FACTORS IN PATIENTS WITH CHRONIC LYMPHATIC LEUKEMIA. A SINGLE CENTRE EXPERIENCE

EHA Library, Viola Popov, 4161754

DYNAMIC INTERVAL DRUG DOSING USING MICROFLUIDIC CELL ARRAY TO INVESTIGATE CHRONIC MYELOID LEUKEMIA CELL-DRUG RESPONSE

EHA Library, Taesung Kim, 4161755

CORRELATION BETWEEN CIRCULATING CD26+ LEUKEMIC STEM CELLS AND BCR::ABL1+ EXTRACELLULAR VESICLES IN CHRONIC MYELOID LEUKEMIA PATIENTS: A PRELIMINARY STUDY

EHA Library, Simona Bernardi, 4161756

METABOLIC REPROGRAMMING IN DRUG RESISTANCE: IN VITRO STUDIES IN MODELS OF CHRONIC MYELOID LEUKEMIA AND MULTIPLE MYELOMA

EHA Library, Ana Bela Sarmento-Ribeiro, 4161757

QUANTIFICATION OF ATYPICAL BCR::ABL1 TRANSCRIPTS BY DIGITAL PCR: AN EUTOS PROJECT

EHA Library, Alice Danzero, 4161758

EXTRACELLULAR VESICLES MOLECULAR FINGERPRINTING WITH FOURIER TRANSFORM INFRARED SPECTROSCOPY: NOVEL APPROACH FOR MONITORING CHRONIC MYELOID LEUKEMIA TREATMENTS

EHA Library, Silvia Mutti, 4161759

THE GAB2 NETWORK IN ACTION: UNVEILING GAB2, GRB2, PIK3R1, AND LYN IN CHRONIC MYELOID LEUKEMIA.

EHA Library, Denise Kusma Wosniaki, 4161760

TYROSINE KINASE INHIBITOR THERAPY ENHANCES STEM CELLS PROFILE AND MAY CONTRIBUTE TO SURVIVAL OF CHRONIC MYELOID LEUKEMIASTEM CELLS

EHA Library, Cristina Panuzzo, 4161761

REDEFINING CML MONITORING: HIGH-PRECISION DIGITAL PCR FOR BCR::ABL1 QUANTIFICATION

EHA Library, Yong-Hwi Kim, 4161762

DECODING INTERMODEL HETEROGENEITY IN CHRONIC MYELOID LEUKEMIA: INSIGHTS FROM IN VITRO EXTRACELLULAR VESICLES' RELEASE

EHA Library, Alessia Cavalleri, 4161763

CHRONIC MYELOID LEUKEMIA MONITORING EXPERIENCE IN ECUADOR, SOLCA - GUAYAQUIL (2015-2024)

EHA Library, Juan Carlos Ruiz-Cabezas, 4161764

CURCUMIN POTENTIATES THE CYTOTOXIC EFFICACY OF IBRUTINIB IN TP53-MUTATED CHRONIC LYMPHOCYTIC LEUKAEMIA CELLS

EHA Library, Xutao Guo, 4161765

NAVIGATING THE LANDSCAPE OF IMATINIB FAILURE IN EASTERN INDIAN CML COHORT : SPOTLIGHT ON NOVEL BCR-ABL1 MUTATIONS, CLINICAL OUTCOMES AND THERAPY SWITCH

EHA Library, Samya Dey, 4161766

CHALLENGES IN TREATING CML PATIENTS IN LOW INCOME COUNTRIES: A SINGLE CENTRE EXPERIENCE

EHA Library, Naqash Suse, 4161767

MAPPING THE METABOLIC RESPONSE OF MALIGNANT HEMATOPOIETIC CELLS TO CHEMOTHERAPY

EHA Library, Akin Bucakci, 4161768

FALSELY NEGATIVE TARGETED NEXT GENERATION SEQUENCING IN CHRONIC MYELOID LEUKEMIA

EHA Library, Dalal Aldhafeeri, 4161769

ENHANCING CHRONIC MYELOID LEUKEMIA SURVEILLANCE: DIGITAL PCR VS RT-QPCR FOR BCR-ABL1 QUANTIFICATION'

EHA Library, Ramlah Mohamed Ibrahim, 4161770

ASSESSING MOLECULAR RESPONSE DEPTH IN PH+ CML PATIENTS: THE ROLE OF REVERSE TRANSCRIPTASE ENZYME SELECTION

EHA Library, Mirjana Suver Stević, 4161771

ASSESSMENT OF T315I MUTATION PREVALENCE AMONG TYROSINE KINASE INHIBITORS-RESISTANT PH+ LEUKEMIA PATIENTS, A TUNISIAN RETROSPECTIVE STUDY

EHA Library, Hadhami Touaiti, 4161772

REAL-WORLD TREATMENT PATTERNS OF TYROSINE KINASE INHIBITORS IN KOREAN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA

EHA Library, Sung-Eun Lee, 4161773

SECOND TREATMENT FREE REMISSION AFTER COMBINATION THERAPY WITH RUXOLITINIB PLUS TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML)

EHA Library, Kendra Sweet, 4161774

CLINICAL FEATURES AND GENETIC ABNORMALITIES PREDICT OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE ACCELERATED-PHASE RECEIVING OLVEREMBATINIB THERAPY: A RETROSPECTIVE MULTICENTER STUDY

EHA Library, Mengyao Yuan, 4161775

DE-ESCALATION AND TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS RECEIVING SALVAGE THERAPY FOR RESISTANCE, WARNING OR LACK OF DEEP MOLECULAR RESPONSE

EHA Library, Delphine Rea, 4161776

DISCONTINUING TKIS IN CML PATIENTS LACKING DEEP MOLECULAR RESPONSE: RISK OR OPPORTUNITY? AN EXPLORATORY STUDY FROM THE ITALY-TFR REGISTRY

EHA Library, Valentina Bonuomo, 4161777

ASCIMINIB AS INITIAL THERAPY WITH ADDITION OF LOWER DOSE TYROSINE KINASE INHIBITORS FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO DO NOT ACHIEVE OPTIMAL RESPONSE OR A DEEP MOLECULAR REMISSION (ALERT CML): A STUDY FROM THE H JEAN KHOURY CURE CML CONSORTIUM (HJKC3)

EHA Library, Michael Mauro, 4161779

EFFICACY AND SAFETY OF FLUMATINIB IN PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE, MULTICENTER, REAL-WORLD STUDY

EHA Library, Yanli Zhang, 4161780

UPDATED PREVALENCE OF CHRONIC MYELOID LEUKAEMIA IN LOMBARDY IN 2024: A MODEL WITH GLOBAL IMPLICATIONS

EHA Library, Federica Colombo, 4161781

APPLICABILITY OF THE HFA-ICOS SCORE AS A CARDIOVASCULAR RISK ASSESSMENT TOOL IN CML PATIENTS

EHA Library, Adrian Segura Díaz, 4161782

REAL-WORLD OUTCOMES OF ASCIMINIB IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA RESISTANT OR INTOLERANT TO TYROSINE KINASE INHIBITORS: A MULTICENTRE CHART REVIEW STUDY IN THE UK

EHA Library, Adrian Choy, 4161783

COMPARATIVE EFFECTS OF THE ALLOSTERIC INHIBITOR ASCIMINIB AND ATP-COMPETITIVE TYROSINE KINASE INHIBITORS ON BONE METABOLISM

EHA Library, Stephanie Sembill, 4161784

ASSESSMENT OF DRUG-DRUG INTERACTION POTENTIAL BETWEEN ASCIMINIB AND ATORVASTATIN IN HEALTHY PARTICIPANTS

EHA Library, Matthias Hoch, 4161785

PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO HAVE NOT ACHIEVED MAJOR MOLECULAR RESPONSE HAD SIGNIFICANTLY INCREASED RISK OF DISEASE PROGRESSION WHEN RECEIVING DE-ESCALATION TYROSINE KINASE INHIBITORS (TKIS) TREATMENT

EHA Library, Bingcheng Liu, 4161786

SEX AFFECTS BOSUTINIB DOSING, TOLERABILITY, AND EFFICACY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: POST HOC ANALYSIS OF THE BODO STUDY.

EHA Library, Susanne Isfort, 4161787

A REAL-WORLD STUDY OF OLVEREMBATINIB IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA FROM CHINA: A SINGLE-CENTER RETROSPECTIVE STUDY

EHA Library, Tian Dong, 4161788

THE OUTCOMES OF CHRONIC MYELOID LEUKEMIA PATIENTS WITH SECONDARY MALIGNANCIES UPON TKI TREATMENT

EHA Library, Zu yingling, 4161789

AN ANALYSIS OF 10 YEARS REAL-WORLD EXPERIENCE OF PONATINIB SAFETY PROFILE

EHA Library, Elias Jabbour, 4161790

UNIQUE GENDER RELATED CHARACTERISTICS AND DIFFERENCES OF CML PATIENTS IN AZERBAIJAN

EHA Library, Aytan Shirinova, 4161791

ASC4REAL: HARNESSING AI TO REVEAL REAL-WORLD INSIGHTS ON THE EFFECTIVENESS OF ASCIMINIB IN PRE- AND POST-PONATINIB TREATED CML PATIENTS

EHA Library, Anchit Khanna, 4161792

HEALTH-RELATED QUALITY OF LIFE IMPROVED IN ADULTS WITH TYROSINE KINASE INHIBITOR-RESISTANT OR INTOLERANT CHRONIC MYELOID LEUKEMIA RECEIVING PONATINIB THERAPY

EHA Library, Lu Yu, 4161794

PREDICTORS OF BLAST PHASE PROGRESSION IN CML: A RETROSPECTIVE ANALYSIS OF IMATINIB-TREATED PATIENTS

EHA Library, Lyam Carlo Chacon-Rangel, 4161795

ACHIEVING TREATMENT FREE REMISSION IN CML PATIENTS TREATED WITH BOSUTINIB: DATA FROM THE ITALY-TFR REGISTRY

EHA Library, Carmen Fava, 4161796

MOLECULAR AND CLINICAL CHARACTERISTICS OF LYMPHOID BLAST CRISIS IN CHRONIC MYELOID LEUKEMIA

EHA Library, Elzbieta Patkowska, 4161797

CLINICAL PHARMACOKINETIC CHARACTERISTICS AND THE EXPOSURE-RESPONSE RELATIONSHIP OF RADOTINIB IN ASIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA

EHA Library, Jangik Lee, 4161798

PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LEUKEMIA WITH CELLS HARBORING BCR::ABL DISCORDANTLY HIGHER THAN BLAST COUNT MAY REPRESENT DE NOVO BLAST PHASE OF CHRONIC MYELOID LEUKEMIA WITH SILENCED CHRONIC PHASE

EHA Library, Endi Wang, 4161800

CLINICAL PHARMACOKINETIC CHARACTERISTICS AND THE EFFECT OF FOOD ON RADOTINIB IN HEALTHY VOLUNTEERS

EHA Library, Yerin Lee, 4161801

ASCIMINIB AS SECOND-LINE THERAPY FOR CHRONIC MYELOID LEUKEMIA: CANADIAN AND INTERNATIONAL REAL-WORLD EXPERIENCE

EHA Library, Maria Agustina Perusini, 4161802

FOLLOW-UP OF ANTITYROSINE KINASE DISCONTINUATION IN THE CONTEXT OF TREATMENT-FREE REMISSION IN PATIENTS FOLLOWED FOR CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE

EHA Library, Yamina Bouchakour Moussa, 4161803

EFFICACY AND SAFETY OF PEGYLATED INTERFERON α-2B IN COMBINATION THERAPY FOR TKI - INEFFECTIVE PATIENTS WITH CML-CP: A REAL-WORLD STUDY

EHA Library, Yunfan Yang, 4161804

TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA FOLLOWING THE SECOND DISCONTINUATION OF TYROSINE KINASE INHIBITORS

EHA Library, Yanli Zhang, 4161805

SYNERGISTIC APOPTOSIS INDUCTION IN MYELODYSPLASTIC SYNDROME CELLS BY AZACITIDINE AND PIM-2 INHIBITORS VIA NUCLEAR FACTOR-KAPPA B PATHWAY INHIBITION

EHA Library, Yixuan Guo, 4161806

CFGF23 BLOCKS MACROPHAGE ACTIVATION IN MYELODYSPLASTIC NEOPLASMS IN VITRO

EHA Library, Karolina Basiak, 4161807

ABNORMAL CHANGES IN MULTIPLE SIGNALING PATHWAYS OF OSTEOBLASTS CULTURED IN VITRO IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND THEIR EFFECT ON NORMAL BONE MARROW CELLS

EHA Library, Shan Gao, 4161808

ACVR1 EXPRESSION IN MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA BASED ON RESPONSE TO HYPOMETHYLATING AGENTS

EHA Library, Kelly Chien, 4161810

LYMPHOPENIA IN PATIENTS WITH MDS IS ASSOCIATED WITH SHIFTS IN SPECIFIC T-CELL SUBPOPULATIONS

EHA Library, Annatina Schnegg-Kaufmann, 4161811

INVESTIGATING THE ROLE OF IMMUNOSURVEILLANCE BY MACROPHAGE IN SUPPORTING THERAPEUTIC STRATEGIES IN MYELODYSPLASTIC SYNDROME

EHA Library, Anya Squires, 4161812

COMPUTATIONAL CLUSTERING OF HAEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCS) REVEALS THAT MYELODYSPLASTIC NEOPLASMS (MDS) DISPLAY A DISTINCT IMMUNOPHENOTYPIC PATTERN ASSOCIATED WITH PROGNOSIS.

EHA Library, Christina Kalpadaki, 4161813

INTERFERON-GAMMAPRODUCTION BY DYSPLASTIC CELLS SUPPORTS AN IMMUNE-TOLERANT BONE MARROW MICROENVIRONMENT IN MYELODYSPLASTIC SYNDROME PATIENTS

EHA Library, Marilena Ciciarello, 4161814

IMPACT OF MOLECULAR ANALYSIS ON LATENCY PERIODS AND THE ROLE OF PRIMARY CANCER HISTORY IN THERAPY-RELATED MYELOID NEOPLASMS

EHA Library, Alessandro Costa, 4161815

EXPRESSION OF IMMUNOMODULATORY MOLECULES ON MAST CELLS IN MYELODYSPLASTIC SYNDROMES: A COMPARATIVE ANALYSIS IN PATIENTS WITH AND WITHOUT CYTOGENETIC ABNORMALITIES

EHA Library, Magdalena Szymańska-Olędzka, 4161816

IPSS-M(R): REDUCED FEATURE REPRESENTATION OF IPSS-M MAINTAINS CLINICAL UTILITY

EHA Library, Vikram Dhillon, 4161817

A COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED (T-MDS) AND 4738 WITH PRIMARY MDS (P-MDS) FOCUSING ON COMPLEX KARYOTYPES

EHA Library, Andrea Kündgen, 4161818

MYELODYSPLASTIC SYNDROME AS A RARE SECONDARY OUTCOME OF CHEMOTHERAPY TREATMENT OF ACUTE PROMYELOCITIC LEUKEMIA: A CASE REPORT

EHA Library, Peterson Gontijo, 4161819

STUDY ON THE MECHANISM OF KIDNEY-REINFORCING AND BLOOD CIRCULATION-ACTIVATING AND DREDGING COLLATERALS DECOCTION IN REGULATING MITOCHONDRIAL FUSION AND APOPTOSIS IN MULTIPLE MYELOMA CELLS

EHA Library, Siyuan Cui, 4161820

SRC KINASES MIGHT BE DIFFERENTIALLY EXPRESSED IN MYELODYSPLASTIC SYNDROMES

EHA Library, Jose Miguel Torregrosa-Díaz, 4161821

PKM AND PKLR MRNA EXPRESSION IN CD34+ CELLS DERIVED FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES

EHA Library, Parija Patel, 4161822

FAMILIAL MYELODYSPLASTIC SYNDROME WITH DDX41 MUTATION EVOLVING TO TP53-MUTATED ACUTE MYELOID LEUKEMIA.

EHA Library, Arthur Gomes Oliveira Braga, 4161823

JUVENILE MYELOMONOCYTIC LEUKEMIA CASE WITH NF1 MUTATION: DIAGNOSTIC AND THERAPEUTIC IMPLICATIONS

EHA Library, Oscar Ramos, 4161824

IMPACT OF MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM ON THE THERAPEUTIC STRATEGY FOR MYELODYSPLASTIC SYNDROMES

EHA Library, Sofia Rincon-Lopez, 4161825

ANEMIA IS THE MOST COMMON CLINICAL MANIFESTATION IN MYELODYSPLASTIC SYNDROMES (MDS) AND ASSOCIATED WITH INCREASED CARDIAC MORBIDITY AND MORTALITY. IN ADDITION TO RED BLOOD CELL UNDERPRODUCTION, SOME MDS PATIENTS DEVELOP HEMOLYTIC ANEMIA, WHICH IS LINKED TO POORER CLINICAL OUTCOMES. THE UNDERLYING PATHOPHYSIOLOGICAL MECHANISMS OF HEMOLYTIC ANEMIA IN MDS, HOWEVER, ARE NOT FULLY UNDERSTOOD. PREVIOUS STUDIES CONDUCTED IN WESTERN POPULATIONS SHOWED THAT MUTATIONS IN U2AF1 AND EZH2 CONTRIBUTE TO HEMOLYSIS. HOWE

EHA Library, Nasawan Ratinanthakul, 4161826

EFFICACY AND SURVIVAL ANALYSIS OF VENETOCLAX AND AZACITIDINE REGIMEN WITH OR WITHOUT SINTILIMAB AND BORTEZOMIB IN THE TREATMENT OF HIGH-RISK MYELODYSPLASTIC SYNDROMES: A REAL-WORLD EVIDENCE ANALYSIS

EHA Library, Liwei Fang, 4161827

MDS/MPN OTHER THAN CMML: ANALYSIS OF AN ITALIAN COOPERATIVE STUDY.

EHA Library, Luca Guarnera, 4161828